Diabetes Epidemic Is a Worldwide Threat
... States. This is even after demonstrating conclusively in the National Institutes of Health’s Diabetes Prevention Program (DPP), and in studies in China ...
... States. This is even after demonstrating conclusively in the National Institutes of Health’s Diabetes Prevention Program (DPP), and in studies in China ...
Freedom Trial
... Model expanding results over lifetime: CABG more economically attractive compared to DES-PCI driven mostly by increase in survival. CABG had an incremental cost-effectiveness ratio of $8,132 per qualityadjusted life-year gained vs PCI. Traditionally, therapies are considered ...
... Model expanding results over lifetime: CABG more economically attractive compared to DES-PCI driven mostly by increase in survival. CABG had an incremental cost-effectiveness ratio of $8,132 per qualityadjusted life-year gained vs PCI. Traditionally, therapies are considered ...
Abstract - WHO archives
... Conclusions: Drug therapy can be optimized by selecting cost-effective natural animal insulin for diabetes patients in a low-income country while also improving access to treatment. Life expectancy and quality of life of diabetic patients can be improved with by strengthening rational drug use, with ...
... Conclusions: Drug therapy can be optimized by selecting cost-effective natural animal insulin for diabetes patients in a low-income country while also improving access to treatment. Life expectancy and quality of life of diabetic patients can be improved with by strengthening rational drug use, with ...
Thailand Diabetes Registry (TDR) Project: Clinical Status and Long
... Socioeconomic status to some extent may affect diabetic complications and mortality as described in a study done in the United Kingdom(7). They found that the mortality rates in type 2 diabetes were higher for those who left school before 16 years of age compared to those who left school at or after ...
... Socioeconomic status to some extent may affect diabetic complications and mortality as described in a study done in the United Kingdom(7). They found that the mortality rates in type 2 diabetes were higher for those who left school before 16 years of age compared to those who left school at or after ...
Chapter 49 Endocrine III – Diabetes Mellitus
... o Meal plan based on individual’s usual food intake and is balanced with insulin and exercise patterns o Insulin regimen managed day to day - Type 2 diabetes mellitus o Emphasis based on achieving glucose, lipid, and blood pressure goals o Calorie reduction - Food composition o Nutrient balance of d ...
... o Meal plan based on individual’s usual food intake and is balanced with insulin and exercise patterns o Insulin regimen managed day to day - Type 2 diabetes mellitus o Emphasis based on achieving glucose, lipid, and blood pressure goals o Calorie reduction - Food composition o Nutrient balance of d ...
Diabetes mellitus
... • Weight loss has been reported to improve insulin sensitivity in obese individuals with type II diabetes. • Exercise may enhance glucose utilization and improve glucose control in patients with type II diabetes, thus reducing the risk of diabetic complications. • Dietary management. • Oral hypoglyc ...
... • Weight loss has been reported to improve insulin sensitivity in obese individuals with type II diabetes. • Exercise may enhance glucose utilization and improve glucose control in patients with type II diabetes, thus reducing the risk of diabetic complications. • Dietary management. • Oral hypoglyc ...
DIABETUS MELLITUS: ETIOLOGY, PATHOGENESIS
... rarely present at diagnosis in type I DM, is present in up to 20 % of type II DM patients at diagnosis. About 85 % of all diabetics eventually develop some degree of retinopathy - the initial retinal changes (seen on the ophthalmoloscopic examination) does not significantly alter vision, but it can ...
... rarely present at diagnosis in type I DM, is present in up to 20 % of type II DM patients at diagnosis. About 85 % of all diabetics eventually develop some degree of retinopathy - the initial retinal changes (seen on the ophthalmoloscopic examination) does not significantly alter vision, but it can ...
diabetes mellitus
... specific problems with microcirculation, neuropathic disorders, and an increased predisposition to atherosclerosis. In that, Diabetes can contribute to or cause the development of blindness, kidney disease, heart disease, leg pains and ulcers (often requiring amputation), complications of pregnancy ...
... specific problems with microcirculation, neuropathic disorders, and an increased predisposition to atherosclerosis. In that, Diabetes can contribute to or cause the development of blindness, kidney disease, heart disease, leg pains and ulcers (often requiring amputation), complications of pregnancy ...
Diabetes - Government of New Brunswick
... Diabetes Diabetes occurs when the glucose (sugar) from food accumulates in the blood instead of being used for energy. In order to use glucose, the body needs insulin, a hormone secreted by the pancreas. ...
... Diabetes Diabetes occurs when the glucose (sugar) from food accumulates in the blood instead of being used for energy. In order to use glucose, the body needs insulin, a hormone secreted by the pancreas. ...
Hepatogenous diabetes in primary care practice – a case study
... • women with polycystic ovarian syndrome (PCOS) • IGT or IFG on previous testing • other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans) • history of CVD 2. In the absence of the above criteria, testing for pre-diabetes and diabetes should beg ...
... • women with polycystic ovarian syndrome (PCOS) • IGT or IFG on previous testing • other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans) • history of CVD 2. In the absence of the above criteria, testing for pre-diabetes and diabetes should beg ...
Emosi dan Diabetes Self
... that one initially felt afraid when required to diet, but the fear gradually disappeared. The result of this study indivated that food management is a diabetic management component which is difficult to accomplish. The patients learned about the 3 J (jenis [type], jadwal [schedule], jumlah [quantity ...
... that one initially felt afraid when required to diet, but the fear gradually disappeared. The result of this study indivated that food management is a diabetic management component which is difficult to accomplish. The patients learned about the 3 J (jenis [type], jadwal [schedule], jumlah [quantity ...
Quantifying the Impact of a Short-Interval Interruption of Insulin
... This prospective, open-label study was designed to measure the impact of short-term infusionset disconnects on glucose levels. Continuous subcutaneous insulin infusion therapy allows for uninterrupted delivery of insulin. Patients disconnect their insulin pumps from their infusion sets when showerin ...
... This prospective, open-label study was designed to measure the impact of short-term infusionset disconnects on glucose levels. Continuous subcutaneous insulin infusion therapy allows for uninterrupted delivery of insulin. Patients disconnect their insulin pumps from their infusion sets when showerin ...
Diabetes Mellitus
... Hadley, M.C. & Levine J.E. (2007). Endocrinology. 6th Edit, Pearson International. Loh, J. A. & Verbalis J. G. (2007). Diabetes insipidus as a complication after pituitary ...
... Hadley, M.C. & Levine J.E. (2007). Endocrinology. 6th Edit, Pearson International. Loh, J. A. & Verbalis J. G. (2007). Diabetes insipidus as a complication after pituitary ...
Prevent India Becoming “Diabetic Capital”
... approximately 439 million people. In this gap of 20 years (2010 to 2030), the increase will be 69%in developing countries and 20% in developed countries. In fact, theproblem is worsening faster than expected as seen by these figures: in 2000, the projected figurefor 2030 was 366 million[1] and by 20 ...
... approximately 439 million people. In this gap of 20 years (2010 to 2030), the increase will be 69%in developing countries and 20% in developed countries. In fact, theproblem is worsening faster than expected as seen by these figures: in 2000, the projected figurefor 2030 was 366 million[1] and by 20 ...
Oestrogen replacement therapy and diabetes
... • Direct effect of hormonal changes (estrogen deficiency, androgen / estrogen ratio) on glucose metabolism regulation : Android distribution of fat mass Insulin resistance ...
... • Direct effect of hormonal changes (estrogen deficiency, androgen / estrogen ratio) on glucose metabolism regulation : Android distribution of fat mass Insulin resistance ...
Rheumatic Musculoskeletal Complaints in Diabetes—Adding
... and epidemiologic studies. Recent work focussing on PTPN22, a protein tyrosine phosphatase nonreceptor, ...
... and epidemiologic studies. Recent work focussing on PTPN22, a protein tyrosine phosphatase nonreceptor, ...
Exercise in children and adolescents with diabetes
... Normal day to day exercise Where exercise is performed regularly, insulin ...
... Normal day to day exercise Where exercise is performed regularly, insulin ...
Nephrotic syndrome in patients with diabetes mellitus is not always
... a recent report, on a cohort of 93 persistent macroalbuminuric patients with type 2 diabetes without retinopathy Christensen et al. w8x, evaluated the cause of renal disease and collected potential demographic, clinical, and laboratory data that may help to separate diabetic from non-diabetic nephro ...
... a recent report, on a cohort of 93 persistent macroalbuminuric patients with type 2 diabetes without retinopathy Christensen et al. w8x, evaluated the cause of renal disease and collected potential demographic, clinical, and laboratory data that may help to separate diabetic from non-diabetic nephro ...
Protocol S1.
... insulin to achieve good metabolic control. Hypoglycemia can cause severe physical and/or psychosocial morbidity and sometimes death, depending on its severity or duration. Central nervous system glucose deprivation (neuroglycopenia) is of major concern as it can lead to irreversible brain damage and ...
... insulin to achieve good metabolic control. Hypoglycemia can cause severe physical and/or psychosocial morbidity and sometimes death, depending on its severity or duration. Central nervous system glucose deprivation (neuroglycopenia) is of major concern as it can lead to irreversible brain damage and ...
Abasaglar, INN-insulin glargine
... the European Union (EU). The reference medicine for Abasaglar is Lantus, which also contains insulin glargine, and studies were designed to compare Abasaglar with Lantus. Studies were carried out to show that the way Abasaglar is absorbed into the body and the way it acts on blood glucose were simil ...
... the European Union (EU). The reference medicine for Abasaglar is Lantus, which also contains insulin glargine, and studies were designed to compare Abasaglar with Lantus. Studies were carried out to show that the way Abasaglar is absorbed into the body and the way it acts on blood glucose were simil ...
Diabetes mellitus (DM), also known as simply diabetes, is a group of
... • Type 2 DM begins with insulin resistance, a condition in which cells fail to respond to insulin properly. As the disease progresses a lack of insulin may also develop. This form was previously referred to as "non insulindependent diabetes mellitus" (NIDDM) or "adult-onset diabetes". The primary c ...
... • Type 2 DM begins with insulin resistance, a condition in which cells fail to respond to insulin properly. As the disease progresses a lack of insulin may also develop. This form was previously referred to as "non insulindependent diabetes mellitus" (NIDDM) or "adult-onset diabetes". The primary c ...
Type 2 Diabetes, Fact Sheet, National Institute
... • National efforts were not being made to combat obesity, a serious risk factor for the disease. Fewer people developed type 2 diabetes compared to today because overweight, obesity, and physical inactivity were not pervasive. ...
... • National efforts were not being made to combat obesity, a serious risk factor for the disease. Fewer people developed type 2 diabetes compared to today because overweight, obesity, and physical inactivity were not pervasive. ...
Diabetes Mellitus
... type 2 and is found to increase postprandial insulin response, delay gastric emptying, suppress glucagon secretion, and reduce appetite ...
... type 2 and is found to increase postprandial insulin response, delay gastric emptying, suppress glucagon secretion, and reduce appetite ...
Medtronic s Path to Develop the Artificial Pancreas
... insulin – a hormone the body needs to regulate blood sugar (glucose). People with type 1 diabetes have to take insulin through injections or insulin pumps, but it can be extremely challenging to determine the right amount based on meals, exercise, stress and changing schedules so glucose levels don’ ...
... insulin – a hormone the body needs to regulate blood sugar (glucose). People with type 1 diabetes have to take insulin through injections or insulin pumps, but it can be extremely challenging to determine the right amount based on meals, exercise, stress and changing schedules so glucose levels don’ ...
Gemigliptin
.svg?width=300)
Gemigliptin (rINN), previously identified as LC15-0444, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It is well known that glucose lowering effects of DPP-4 inhibitors are mainly mediated by GLP-1 and gastric inhibitory polypeptide (GIP) incretin hormones which are inactivated by DPP-4.Gemigliptin was initially developed solely by LG Life Sciences. In 2010, Double-Crane Pharmaceutical Co. (DCPC) joined with LGLS to co-develop the final compound and collaborate on the marketing of the drug in China. LGLS also announced on Nov., 2010 that NOBEL Ilac has been granted rights to develop and commercialize gemigliptin in Turkey.A New Drug Application (NDA) for gemigliptin in the treatment of type 2 diabetes was submitted to the Korea Food & Drug Administration (KFDA) in July 2011. Then on June 27, 2012, the KFDA has approved the manufacture and distribution of LG Life Sciences’ diabetes treatment, Zemiglo, the main substance of which is gemigliptin. Clinical trials for evaluating the safety and efficacy of gemigliptin in combination with metformin have been completed.